Vevye was Harrow’s largest product and service line in fiscal 2025, bringing in $266.06M of $818.09M (33%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Product Sales Net | $250.57M | $239.81M | $250.50M | $229.64M | |||||
| Product Sales, Net | — | — | — | — | |||||
| Iheezo | — | $61.86M | $147.91M | $244.04M | |||||
| Vevye | — | $5.30M | $84.18M | $266.06M | |||||
| Other Products | — | $45.38M | $113.51M | $75.98M | |||||
| Other Revenue | — | $38.24M | $2.75M | $1.18M | |||||
| Other Revenues | — | $38.24M | $2.99M | $1.18M | |||||
| Commissions | $11.60M | — | — | — | |||||
| Transfer Of Acquired Product Sales Profits | $3.62M | — | — | — | |||||
| Transfer Of Profit | — | — | — | — | |||||
| License Revenues | — | — | — | — | |||||
| License | — | — | — | — | |||||
| Total | $265.79M | $428.82M | $601.83M | $818.09M |
Harrow brought in $818.09M from its six product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 35.9% from $601.83M in fiscal 2024. Vevye was the largest at $266.06M (32.5%), ahead of Iheezo at $244.04M (29.8%) and Product Sales Net at $229.64M (28.1%). The other three lines brought in $78.34M combined.
Compared with fiscal 2024, Vevye grew fastest, up 216.1% to $266.06M, while Other Products fell the most, down 33.1% to $75.98M.
Harrow began breaking out Iheezo in fiscal 2023, Vevye in fiscal 2023, Other Products in fiscal 2023 and Other Revenue in fiscal 2023. Harrow stopped reporting Commissions ($11.60M in fiscal 2022) and Transfer Of Acquired Product Sales Profits ($3.62M in fiscal 2022) as separate lines.
Branded was Harrow’s largest segment in fiscal 2025, bringing in $586.09M of $815.73M (72%).
| Segment | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Branded | $112.54M | $345.36M | $586.09M | |||
| Imprimisrx | $239.81M | $250.50M | $229.64M | |||
| Pharmaceutical Compounding | — | — | — | |||
| Total | $352.34M | $595.86M | $815.73M |
Harrow brought in $815.73M from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 36.9% from $595.86M in fiscal 2024. Branded was the largest at $586.09M (71.8%), ahead of Imprimisrx at $229.64M (28.2%).
Compared with fiscal 2024, Branded grew 69.7% to $586.09M, while Imprimisrx fell 8.3% to $229.64M. From fiscal 2023 to 2025, combined revenue from these segments grew from $352.34M to $815.73M, a compound annual growth rate of 52.2%. Branded's share of the total rose from 31.9% to 71.8%.
Harrow (HROW) reports its revenue by product and service and by segment. In fiscal 2025, Vevye was its largest product and service line, bringing in $266.06M (32.5% of the total), followed by Iheezo at $244.04M (29.8%).
Vevye was Harrow's largest product and service line in fiscal 2025, bringing in $266.06M, or 32.5% of the $818.09M total across its six product and service lines.
Branded was Harrow's largest segment in fiscal 2025, bringing in $586.09M, or 71.8% of the $815.73M total across its two segments.
Among Harrow's product and service lines that make up at least 2% of revenue, Vevye grew fastest in fiscal 2025, up 216.1% from $84.18M to $266.06M.
Every figure comes from Harrow's annual financial filings, as reported. Each line keeps the name Harrow gives it, and years follow its fiscal calendar.
Harrow's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.